Research Directory

Stock market performance, Q4 was a difficult quarter for European biotech, by Robin Davison

Read more

Europe's biotech sector enjoys better Q3

Read more

Europe's capital markets continue to struggle

Read more

Provincialism holds back Europe's biotech sector

Read more

Long overdue, the EU capital markets plan is revived

Read more

Precision medicine is theme in quiet Q3 share market

Read more

Q2 stocks: Trial results, regulatory nods help European shares

Read more

Stock values decline and companies restructure

Read more

Q4 2022 Stock Comment

Read more

Biotech companies advised to conserve cash

Read more